SONN vs. TFFP, PTIX, CING, FWBI, ADXS, GNPX, HOTH, SNPX, XBIO, and KTRA
Should you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include TFF Pharmaceuticals (TFFP), Protagenic Therapeutics (PTIX), Cingulate (CING), First Wave BioPharma (FWBI), Ayala Pharmaceuticals (ADXS), Genprex (GNPX), Hoth Therapeutics (HOTH), Synaptogenix (SNPX), Xenetic Biosciences (XBIO), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Sonnet BioTherapeutics (NASDAQ:SONN) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
Sonnet BioTherapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
TFF Pharmaceuticals received 50 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 67.68% of users gave TFF Pharmaceuticals an outperform vote.
Sonnet BioTherapeutics has higher earnings, but lower revenue than TFF Pharmaceuticals.
9.5% of Sonnet BioTherapeutics shares are owned by institutional investors. Comparatively, 15.3% of TFF Pharmaceuticals shares are owned by institutional investors. 2.0% of Sonnet BioTherapeutics shares are owned by company insiders. Comparatively, 5.6% of TFF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
TFF Pharmaceuticals has a net margin of -2,897.95% compared to Sonnet BioTherapeutics' net margin of -11,187.19%. TFF Pharmaceuticals' return on equity of -163.14% beat Sonnet BioTherapeutics' return on equity.
Sonnet BioTherapeutics currently has a consensus target price of $30.00, suggesting a potential upside of ∞. TFF Pharmaceuticals has a consensus target price of $72.00, suggesting a potential upside of 3,344.98%. Given Sonnet BioTherapeutics' higher possible upside, research analysts clearly believe Sonnet BioTherapeutics is more favorable than TFF Pharmaceuticals.
In the previous week, Sonnet BioTherapeutics had 1 more articles in the media than TFF Pharmaceuticals. MarketBeat recorded 1 mentions for Sonnet BioTherapeutics and 0 mentions for TFF Pharmaceuticals. Sonnet BioTherapeutics' average media sentiment score of 0.22 beat TFF Pharmaceuticals' score of 0.00 indicating that Sonnet BioTherapeutics is being referred to more favorably in the media.
Summary
TFF Pharmaceuticals beats Sonnet BioTherapeutics on 8 of the 14 factors compared between the two stocks.
Get Sonnet BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sonnet BioTherapeutics Competitors List
Related Companies and Tools
